Platinum complex cytotoxicity tested by the electrical resistance breakdown assay

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Platinum-based chemotherapy is a cornerstone in cancer treatment.
• Assessing cancer cell invasiveness and drug efficacy requires sensitive, functional assays.
• Current methods like the MTT assay primarily measure cytostatic activity, not invasiveness.

Purpose of the Study:

• To introduce and validate a novel electrical resistance breakdown assay for quantifying cancer cell invasiveness.
• To evaluate the efficacy of platinum-based anticancer drugs (cisplatin, oxaliplatin, carboplatin) using this new assay.
• To compare the performance of the electrical resistance breakdown assay with the standard MTT assay.

Main Methods:

• Utilized a transepithelial electrical resistance (TEER) assay with a tight epithelial MDCK-C7 monolayer.
• Introduced highly invasive amelanotic melanoma cells (A7-clone) onto the monolayer.
• Measured TEER changes in response to platinum complexes and compared results with the MTT assay.

Main Results:

• Electrical resistance breakdown, indicative of cell invasion, occurred within 48 hours of co-culture.
• Cisplatin and its analogs effectively prevented TEER breakdown.
• The electrical resistance breakdown assay results were linearly dependent on MTT assay results, but provided additional functional information on invasiveness.

Conclusions:

• The electrical resistance breakdown assay is a sensitive, continuous, cell-based system for quantifying cancer cell invasiveness.
• This assay allows for the evaluation of chemotherapeutics under physiological conditions.
• Cisplatin demonstrated efficacy in reducing both tumor cell number and invasiveness.